News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Opinion|Videos|April 16, 2024

Examining the Role of Liver Function in HCC

Author(s)Richard Finn, MD, David James Pinato, MD, MRCP, PhD

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, discuss driving forces for the development of hepatocellular carcinoma, including different types of viral hepatitis and non-alcoholic steatohepatitis.

Episodes in this series

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, experts on hepatocellular carcinoma

EP. 1 Examining the Role of Liver Function in HCC

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, experts on hepatocellular carcinoma

EP. 2 HCC Staging: Improving Treatment Strategies

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, experts on hepatocellular carcinoma

EP. 3 Locoregional Therapies for Intermediate-Stage HCC

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, experts on hepatocellular carcinoma

EP. 4 HCC Trials: Insights from the LAUNCH, EMERALD-1, and LEAP-012 Trials

Video 5 - "Emerging Therapies in Intermediate-Stage HCC"

EP. 5 Emerging Therapies in Intermediate-Stage HCC

Video 6 - "Updates from IMbrave150, LEAP-002, and HIMALAYA Trials"

EP. 6 Updates from IMbrave150, LEAP-002, and HIMALAYA Trials

Video 7 - "Comorbidity Considerations for HCC Treatment"

EP. 7 Comorbidity Considerations for HCC Treatment

Video 8 - "The Evolving Landscape of Second-Line Therapies in HCC Management"

EP. 8 The Evolving Landscape of Second-Line Therapies in HCC Management

Video 9 - "Additional Second-Line Treatments for HCC"

EP. 9 Additional Second-Line Treatments for HCC

Video 10 -"Real-World Evidence on Second-Line Therapy Selection and Outcomes"

EP. 10 Real-World Evidence on Second-Line Therapy Selection and Outcomes

Video 11 - "Pioneering Breakthroughs in HCC Treatment"

EP. 11 Pioneering Breakthroughs in HCC Treatment

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related to this article

FDA

July 13th, 2026

FDA Issues Third CRL for Rivoceranib Plus Camrelizumab in First-Line HCC Over Additional Manufacturing Concerns

The decision does not reflect new concerns about the clinical efficacy or safety data from the phase 3 CARES-310 trial.

Trending on OncLive

FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC

FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications

Sacituzumab Govitecan Yields Responses in Platinum-Resistant Ovarian Cancer

Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC

Dr Mardones on Giredestrant Plus Palbociclib in Estrogen Receptor+ Breast Cancer